During the past decade, Johns Hopkins Oncology Center ORA conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 1 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Johns Hopkins Oncology Center ORA" are "Non-Hodgkin Lymphoma" (1 trials) and "Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia" (1 trials). Many other conditions were trialed in "Johns Hopkins Oncology Center ORA" in a lesser frequency.

Most popular intervention types in "Johns Hopkins Oncology Center ORA" are "Drug" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Bridging Therapy" (1 trials), "Tisagenlecleucel" (1 trials), "lymphodepleting chemotherapy" (1 trials) and "nilotinib" (1 trials). Other intervention names were less common.

The vast majority of trials in "Johns Hopkins Oncology Center ORA" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Johns Hopkins Oncology Center ORA". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Johns Hopkins Oncology Center ORA, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Johns Hopkins Oncology Center ORA, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".